New AI Liquid Biopsy Accurately Detects Early-Stage Pancreatic Cancer

A multi-center international study involving nearly 1,800 patients demonstrated that an investigational blood-based liquid biopsy test can detect early-stage pancreatic ductal adenocarcinoma with 87% accuracy. Developed by researchers at City of Hope, the assay combines circulating microRNAs, exosomal microRNAs, and the CA19-9 protein score using artificial intelligence to identify malignancy before symptoms manifest.

Pancreatic cancer remains one of the most lethal oncological diagnoses worldwide. For the vast majority of patients, the disease is identified only after it has metastasized to surrounding organs, rendering surgical resection impossible. Current diagnostic pathways rely heavily on cross-sectional imaging and invasive procedures that are typically deployed only after clinical presentation occurs. This diagnostic lag directly impacts survival statistics. The five-year relative survival rate drops precipitously from roughly 44% for early-stage disease down to approximately 3% once the malignancy reaches late stages.

Evaluating the Diagnostic Mechanism and Biomarkers

The investigational assay, evaluated in research published in Nature Medicine and presented at the American Association for Cancer Research annual meeting, takes a multi-analyte approach. Led by Dr. Ajay Goel, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at City of Hope, the research team focused on overcoming the limitations of single-marker tests. The assay measures free-floating microRNAs alongside exosomal microRNAs—small RNA molecules packaged inside microscopic extracellular vesicles that act as a biological ZIP code, allowing investigators to trace the molecular origin of the signal back to the pancreas.

By pairing these microRNA signatures with the traditional protein biomarker CA19-9 and running the dataset through an artificial intelligence algorithm, the test generated a unified risk score. In validation cohorts spanning the United States, Europe, and Asia, the assay correctly flagged stage 1 and stage 2 pancreatic tumors 87% of the time. Furthermore, the combined approach identified roughly 97% of early-stage cases when optimized. Beyond invasive carcinoma, the liquid biopsy also detected high-grade dysplasia—an advanced precancerous state often termed stage 0 pancreatic disease—in more than 64% of instances, offering a potential window for clinical intervention before malignant transformation takes hold.

In Plain English: The Clinical Takeaway

• What is a liquid biopsy? It is a blood test that looks for tiny genetic fragments and proteins released by tumors, rather than requiring a tissue sample from a surgical biopsy.
• Why do exosomes matter? Exosomes are tiny protective sacs released by cells. Because pancreatic cells leave unique molecular markings on their sacs, researchers can tell if the cancer signal specifically originates in the pancreas.
• What is high-grade dysplasia? This refers to severely abnormal, precancerous cellular changes found inside pancreatic cysts. Catching these changes early allows physicians to monitor or intervene before invasive cancer develops.

Epidemiological Integration and Triage Strategies

Despite high sensitivity, applying broad population-level screening for pancreatic cancer presents severe statistical hurdles due to the low baseline prevalence of the disease in the general public. As noted by Dr. Matthew Young, co-lead program director of the National Cancer Institute’s Pancreatic Cancer Detection Consortium, even a diagnostic tool with near-perfect accuracy would generate a high volume of false-positive results in an unselected population. Because a positive screening result typically necessitates an invasive abdominal surgery to confirm or rule out malignancy, deploying such a test indiscriminately would expose healthy individuals to unnecessary surgical morbidity.

Photo: europesays.com

Consequently, clinical consensus points toward targeted screening for high-risk cohorts. This includes individuals harboring inherited genetic mutations linked to familial pancreatic cancer, those with a strong family history of the disease, patients managing chronic pancreatitis, and individuals presenting with new-onset diabetes or under active surveillance for pancreatic cysts. For these patients, the positive predictive value of a liquid biopsy justifies the clinical follow-up required by regional healthcare systems.

Biomarker Component	Biological Role	Contribution to Assay
Circulating microRNAs	Freely floating RNA fragments shed into the bloodstream by dying or active tumor cells.	Provides high abundance signals indicating the presence of oncology-related activity.
Exosomal microRNAs	RNA packaged within membrane-bound vesicles carrying organ-specific surface markers.	Acts as a biological ZIP code to confirm the pancreas as the source of the pathology.
CA19-9 Protein	A well-established tumor-associated carbohydrate antigen frequently elevated in pancreatic malignancies.	Enhances overall sensitivity when combined with RNA panels, capturing up to 97% of early cases.

Contraindications & When to Consult a Doctor

The investigational liquid biopsy is not currently cleared for routine diagnostic use outside of approved clinical trial protocols. Patients must understand that this assay is designed to assist physicians in risk stratification, not to replace cross-sectional imaging such as endoscopic ultrasound or computed tomography scans.

Photo: cancer.gov

Future Trajectory and Regulatory Path

Funding for the underlying research was provided by the National Cancer Institute through the Pancreatic Cancer Detection Consortium. Before this assay transitions into standard clinical workflows across North America, Europe, and Asia, independent replication studies and formal prospective validation trials must be completed to satisfy regulatory standards.

“Pancreatic cancer remains so deadly largely because we find it after the window for cure has begun to close,” stated Dr. Ajay Goel regarding the imperative for continued clinical investigation. As multi-center trials progress, the refinement of AI-driven multi-analyte blood assays moves clinical oncology closer to shifting stage presentation and extending survival horizons for vulnerable patient populations.

References

• National Cancer Institute. (2024). microRNA-Based Liquid Biopsy Detects Early Pancreatic Cancer. Cancer Currents Blog. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2024/liquid-biopsy-detects-pancreatic-cancer
• Europe Says. (2025). Could a liquid biopsy detect pancreatic cancer at its earliest stages. Health News Archive. Available at: https://www.europesays.com/health/54620/
• American Association for Cancer Research (AACR). Annual Meeting Proceedings on Early Cancer Detection and Biomarkers.

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.